Summary
Urine from 5 renal transplant recipients treated with frusemide was analyzed for unchanged frusemide (F), glucuronidated frusemide (G) and 4-chloro-5-sulfamoylanthranilic acid (CSA) by HPLC.
In 3 recipients, whose renal function recovered steadily and whose hepatic function was normal throughout, the ratio of frusemide to its metabolites, F/(F+G+CSA), increased steadily in conjunction with the recovery of renal function. In one patient, who received frusemide 200–400 mg/day i.v., the urinary CSA concentration was 64–102 µg·ml−1. In 2 patients who experienced shock and/or hepatic dysfunction after transplantation, the F/(F+G+CSA) ratio fluctuated.
This is a preview of subscription content, log in via an institution to check access.
References
Smith DE, Lin ET, Benet LZ (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite specific assay. Drug Metab Dispos 8: 337–342
Benet LZ, Smith DE, Lin ET, Vincenti F, Gambertoglio JG (1983) Furosemide assays and disposition in healthy volunteers and renal transplant patients. Fed Proc 42: 1695–1698
Smith DE, Benet LZ (1983) Biotransformation of furosemide in kidney transplant patients. Eur J Clin Pharmacol 24: 787–790
Andreasen F, Christensen CK, Jakobsen FK, Mogensen CE (1981) The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol 49: 223–229
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakahama, H., Miwa, Y., Yamaji, A. et al. The urinary excretion of frusemide and its metabolites by kidney transplant patients. Eur J Clin Pharmacol 32, 313–315 (1987). https://doi.org/10.1007/BF00607581
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607581